Age >=  years at the NCI clinical center (>=  years at other participating sites)
Medulloblastoma:\r\n* Posterior fossa classic, desmoplastic or extensive nodular or anaplastic/large cell medulloblastoma with appropriate and sufficient tumor material (FFPE or snap frozen) for proposed assays: all stages, age less than  years at diagnosis\r\n* Posterior fossa classic or anaplastic/large cell medulloblastoma with sufficient tumor material (FFPE or snap frozen) for proposed assays: clinically high-stage (neuraxis or extra-neural dissemination, M-), age greater than  years to less than  years at diagnosis\r\n* Posterior fossa medulloblastoma, those  years of age and above at diagnosis, will only be eligible if they have evidence of neuraxis or extraneural dissemination. Patients  years of age and above with low-stage (standard-risk, M) medulloblastoma will NOT be eligible for this study, irrespective of molecular subgroup and extend of local resection
Parts A & C: patients must be >=  months and <  years of age at the time of study enrollment
Parts B-B, B, D-D, E, E: patients must be >=  months and =<  years of age at the time of study enrollment
Part B: patients must be >=  months and <  years of age at the time of study enrollment
Eligible Ages in Australia and Canada;  years to  years
Age of  years or older; in addition, patients age  to  years may enroll beginning in Cohort  if weight ?  kg
Patients with body mass index (BMI) < rd percentile for age, as defined by WHO criteria for patients - years of age and Centers for Disease Control and Prevention (CDC) criteria for patients >  years of age, are not eligible
Participants who are less than  years of age at start of maintenance chemotherapy
Part A: Patients must be >=  months and =<  years of age at the time of study enrollment
Standard risk : Patient must be <  years of age at enrollment
Standard risk : Patients must be >=  and <  years of age at enrollment
Hemoglobin >=  g/dL for patients =<  years of age; >=  g/dL for patients >  years of age; Note: no transfusions are permitted  days prior to laboratory studies to determine eligibility
Efficacy Phase: Patients must be =<  years of age at the time of enrollment
Age ? years (or per national guidelines).
Adult patients ?  years
Subjects must be age ?  years at initial diagnosis
Subjects must be age ?  years at initial diagnosis
Adults (Age ?  years)
Adults age - years
 years of age or order
Subjects ? years of age for solid tumor; in the case of midline carcinoma with NUT rearrangement. subjects may be ? years of age.
Patients must fit into one of the following categories:\r\n* Age >=  years to <  years with a cumulative illness rating scale (CIRS) score >=  OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >=  years
Pts must be ?  years of age
Must be less than  years of age at time of original diagnosis
Be between the ages of ? and ? years
St. Jude patients must be between  years and =<  years of age, on therapy (active patient), or within  years of completion of therapy; patients treated at collaborating sites must be =<  years old
Male or female participants age ? years (or any age ? years if that age is considered to be an adult per the local jurisdiction) at the time of informed consent
 years of age at the time of consenting.
Age ? . years and < . years at the time of enrollment.
Patients =<  years of age will be eligible for the pre-surgical cohort; patients between - years of age will be treated at the adult Food and Drug Administration (FDA)-approved dose of  mg BID and can be enrolled immediately; patients less than  years of age will be enrolled and treated at the pediatric MTD once it is defined in the safety cohort
Patients =<  years of age with evaluable disease will be eligible for the expansion cohort; patients between  and  years of age will take adult dose of  mg BID and are eligible at the initiation of the trial; patients less than  years of age will take the MTD once it is defined in the safety cohort
Must be ?  years of age. Due to increased risk of sepsis in patients > years old, candidate patients in this age group should be thoroughly evaluated prior to study randomization to ensure they are fit to receive chemotherapy. In addition to all of the inclusion/exclusion criteria listed, clinical judgment should be used regarding patients' susceptibility to infection (including but not limited to presence of ascites or diabetes mellitus increasing risk of infection). Furthermore, the expected stability of their performance status while receiving repeat weekly chemotherapy cycles should be given special attention. Patients in this age group should not be randomized on the study should there be any hesitation on any of these considerations.
Patient is <  years of age at time of enrollment.
Participants with  to less than (<)  years of age (Part  only), or  to  years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at < years of age (Part  only)
Age: ?  years at the time of study entry.
Age >=  years or age of majority at the participating site, whichever is greater
Patients must be less than  years of age at the time of diagnosis.
Age ? years. Because no dosing or adverse event data are currently available on the use of ipilimumab or indoximod in patients < years of age, children are excluded from this study.
Age >=  year and <  years at the time of screening; exception: participants with recurrent, progressive, or refractory medulloblastoma and are >=  and <  years of age at the time of study screening are eligible for screening
STRATUM A: Age >=  year and <  years at the time of screening
STRATUM B: Age >=  year and <  years at the time of study enrollment
STRATUM C: Age >=  years and <  years at the time of study enrollment
Age > years and ?  years at the time of enrollment
Patient is at least  years of age and < years of age at the time Informed Consent is signed.
The pediatric cohort is defined as age younger than  years.
Patients ? years of age at the time of signature of the ICF
Age:\r\n* Phase : >=  and =<  years of age at time of enrollment\r\n* Phase : >=  and =<  years of age at diagnosis
Adults ? years of age
Adults ? years of age
Patient age criteria: age >=  and =<  years (myeloablative regimen ; age >=  and =<  years (nonmyeloablative regimen ) at the discretion of the investigator(s); age >=  and =<  years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 
Appropriate written consent  adult or parent/guardian if patient is <  years of age and minor information sheet if patient is >  years of age
Age >=  to <  years; patients  to  years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
Age  months - . years at enrollment
Age (at the time of consent/assent): ? years of age
< % for patients <  years,
Age >  years at time of study entry
Age <  years and at least  of the following conditions:
Patients must be > than  months and ?  years of age at the time of study enrollment.
Males and females  years of age and older; subjects <  years of age that meet any of the following criteria: \r\n* Subjects that refuse to be treated with chemotherapy based agents (this should be documented in the consent form)\r\n* Subjects that are not candidates for treatment with chemotherapy agents based on any of the following:\r\n** ECOG performance status >= \r\n** Cumulative illness rating scale (CIRS score) >= \r\n** Creatinine clearance <  mL/min using the Cockcroft-Gault equation
Age: ?  years at the time of diagnosis.
Any patient with both metastatic ependymoma and age <  years at the time of enrollment
Pediatric patients (age - years) will be entered only after  adult patients have been entered without dose limiting toxicity
Age: up to and including  years at diagnosis of Haemophagocytic Lymphohistiocytosis
Be between the ages of ? and ? years
Age: \r\n* Stratum I (TMI containing arm): - years of age\r\n* Stratum II (non TMI arm): - years of age
within the last  years OR
Postmenopausal defined as women > years of age with amenorrhea for ?  years prior to screening
> years
Age ?  years at the time of screening or age of consent according to local law
Age  years and  year or more of amenorrhea
Age >  years. Because no dosing or adverse event data are currently available on the use of AR- in patients <  years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
Man or woman, age > years
Stratum  (IDH wild-type): Patients must be >=  years of age and =<  years of age at the time of enrollment
Stratum  (IDH mutant): Patients must be >=  years of age and =<  years of age at the time of enrollment
Minimum age  years (in Japan, minimum age  years).
One of the following:\r\n* Age >=  years\r\n* Age <  years but unsuitable for standard chemotherapy because of a cardiac ejection fraction of < %, a pulmonary diffusion capacity < %, or a creatinine clearance >=  and <  mL/min, or refused standard chemotherapy despite efforts to convince them otherwise
Age (must have body surface area [BSA] >= . m^):\r\n* Phase I: >=  and =<  years of age\r\n* Phase II: >=  and =<  years of age
>  years of age must be approved by principal investigator
Minimum Age  years (in certain territories, the minimum age requirement may be\n             higher eg age  years in Japan and Taiwan)
Age:\r\n* Part A: Patients must be >=  months and <  years of age at the time of study enrollment\r\n* Part A: Patients must be >  months and <  months of age at the time of study enrollment; patients will enroll one dose level behind the dose level at which patients in Part A are enrolling
Age:\r\n* Phase  (Part A)\r\n** Patients must be > than  months and =<  years of age at the time of study enrollment\r\n* Phase  (Part B and Part C)\r\n** Patients must be > than  months and =<  years of age at the time of study enrollment
Serum estradiol level assay (required for patients <  years of age and one year or more of amenorrhea) <  pg/mL
Age (at the time of consent/assent): ? months to ? years
Cohort  only: ? years to ? years
Age  -  years; age >  allowed at investigator discretion if performance status ? ; and each organ system score ?  using cumulative illness rating scale (CIRS)
Age ?  years or the minimum legal adult age (whichever is greater) at the time of Informed consent.
Age <  years and >  month (<  month upon approval by Sponsor)
Patients must be >  months and <  years of age when registered on study.
Patients must be >  years and <  years of age when registered on study.
Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >= years; or participants less than (<)  years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below  years of age is required before randomization
Age ?  years and one year or more of amenorrhea
Age <  years and one year or more of amenorrhea, with an estradiol assay <  pg/mL
Age ? years at the time of screening
At least  years of age Except: where local regulations and/or institutional policies do not allow for subjects <  years of age (pediatric population) to participate. For those sites, the eligible subject population is ?  years of age
Men and women  years of age to  years of age of any ethnic origin or race at the time of signing the ICD.
Age superior or equal to  years or country's legal age of majority if the legal age is superior to  years old.
Patients must be ?  months of age and ?  years of age at the time of study entry for patients diagnosed with DIPG.
Patients must be ?  months of age and ?  years of age at the time of study entry for patients diagnosed with HGG.
Adult women (?  years of age) with advanced TNBC.
Male or female, greater than or equal to (>=)  years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is >  years of age); [i.e. >=  years of age in Japan])
Patient is at least  years of age at randomization.
Age ? years (?  years in Japan).
Cohort  patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) .\r\n* Note: patients in Cohort  will be stratified as follows:\r\n** Stratum : Patients >=  years of age but <  years\r\n** Stratum : Patients >=  years of age but <  years
Adults ?  years of age.
Age  years or younger at the time of initial ALL diagnosis and age >  year at the time of study treatment initiation.
Minimum age in Japan is  years.
Age >=  years and not candidates for conventional cytotoxic chemotherapy or refuse it; OR patients below the age of  years who are considered unfit and/or unable to tolerate standard chemotherapy at the discretion of the treating physician or the principal investigator
Adult patient, >/=  years of age
Males and female subjects ?  years of age at the time of enrollment, except in Japan where subjects must be ?  years of age at the time of enrollment
Age - years at the time of diagnosis of AML
Subjects younger than  years of age
Female gender and age ?  years at time of study entry
F FLT CANDIDATE TRANSPLANT RECIPIENT: Age >=  years old at National Cancer Institute (NCI), and age >  years and <  years at Childrens National Medical Center
E . Less than  years (or country's legal age of majority if the legal age is > years).
Unable to receive intensive chemotherapy regimens at enrollment, based on one of the following: I. Age ?  years, or II. Age <  years with at least  of the following co-morbidities:
Age ? years. A patient may be of either sex and of any race/ethnicity.
For ESFT patients age ? years.
For ESFT patients age ? years.
Age ? years (non-ESFT candidates)
Age >=  years (age >  years to participate in optional symptom burden assessment)
Minimum age  years (in certain territories, the minimum age requirement may be higher (e.g.  years in Japan and Taiwan)
Patients must be ? and ?  years of age when originally diagnosed with ALL. Diagnosis
Male or female outpatients (except where inpatient stay is required for medical need at the Investigator's discretion) at least  years of age at the time of informed consent
Prior radioimmunotherapy within  years of enrollment
Patients over  years of age, regardless of race of gender
Patients younger than  years of age
Adult patients, >/=  years of age
Adult patients, >/=  years of age
Patients must be ?  years of age at the time of enrollment.
At least  years of age at time of study entry
Adult patient, >/=  years of age
Adult participants, >/=  years of age
Adult patients, >/=  years of age
? years.
Participants must be ? years since no dosing or adverse event data are currently available on the use of OGX- in participants < years of age.
Is  months (at least  weeks gestation) to < years of age
Patients must be <  years of age when registered on study.
For the initial dose escalation to identify the maximum tolerable or PK target dose, age between  years and < years (inclusive) at the time of signing the informed consent form. Children <  years of age will be enrolled once the age specific expansion cohorts are open.
PHASE I: >=  years and =<  years of age at the time of study enrollment, if able to swallow whole capsules
Adults >  years of age
Adult patients, >/=  years of age
Patient is ?  years of age on the day of consent signature
Adults >/= years
Participants must be <  years of age at the time of study entry\r\n* Participants currently on therapy at St. Jude, or within  years of completing therapy at St. Jude must be =<  years of age\r\n* Other participants must be =<  years of age
Patients up to  years of age at time of registration with a diagnosis of SAA; SAA is defined as follows:
Ages - years,
The parent must be at least  years of age to ensure the age of majority across all participating sites to legally consent their child
 to  years of age at diagnosis of first cancer
Age ?  years at the time of screening.
The child is - years of age at time of enrollment
One parent (?  years of age) can be present for all sessions
PROVIDER ELIGIBILITY: The participant is greater than  years of age
Ages - years
EXCLUSION FOR PARENTS: Parent is <  years of age
PHASE A: AYA SURVIVOR ELIGIBILITY: At least  years from treatment for any pediatric cancer diagnosed at age -
PHASE B: PATIENT ELIGIBILITY: At least  years from treatment for any pediatric cancer diagnosed at age -
Co-survivors must be over the age of  years
Qualitative interviews will be conducted in patients (age  years or older) with their assent/consent; patients (age -. years) will be asked to complete surveys that have been validated in this age group and that offer insight into the usefulness of the BMT Roadmap; patients ( years or older) will be asked to complete surveys
Child: child is age  to  years,  months
Age\r\n* For centers that will use fluconazole as the antifungal comparator:\r\n** Age >=  months and <  years\r\n* For centers that will use voriconazole as the antifungal comparator:\r\n** Age >=  years and <  years
Off treatment >  years
Is ? years or the minimum legal adult age (whichever is greater) and ? years (at Screening);
For dose-escalation stage (tablets): age at study entry >=  years to <  years
For dose-escalation stage (suspension): age at study entry >=  months to <  years. Participants < year of age will not be enrolled until >=  participants >=  year to <  years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted.
For expansion stage: age at study entry to be >=  months (>= years if suspension is not available) to <  years. Participants >=  months to <  year of age may not be enrolled until >=  participants >=  year to <  years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted.
Age - years at time of study enrollment
Bone Mineral Density (BMD) requirements: Osteopenia if under  years of age; Osteopenia or normal BMD if over  years of age
Were diagnosed with a childhood cancer prior to the age of  years
Have at least  relatives with breast cancer on the same side of the family, one of which is =<  years of age
RECIPIENT: Age  to  years
Age >=  years for the feasibility phase; age >=  years old AND >=  kg for the phase II portion
Have smoked for at least  years;
At time of approach, >=  years from initial cancer diagnosis or >=  years from first HCT, whichever is later.
Adult (? years)
Age: - years at the time of diagnosis.
Age: - years at the time of diagnosis.
Age: - years at the time of diagnosis.
Mammogram negative for breast cancer within the  months preceding the time of registration for women >=  years of age
Is  (at least  weeks gestation) to  years of age at time of randomization
Between . years and < . years of age at the time of recruitment
Age ?  years and one year or more of amenorrhea
Age <  years and one year or more of amenorrhea, with an estradiol assay <  pg/ml
Adult patients at least  years of age
Individuals who are less than  years of age
Signed written informed consent (by parent if patient is <  years of age, or by patient, if he or she is >=  years of age)
Patient assent for those >=  years of age and <  years of age for whom a parent provides informed consent
Male or females with an age ?  years (?  years in Japan)
Adult male >/=  years of age
Females ?  years of age presenting for routine cervical cancer screening.
Pediatric patients of any age are eligible, including those that may require sedation for MRI; more specifically, children - years of age and adults >=  years of age are eligible
Adult patients over  years of age;
Patients younger than  years
Age: > month and < years at time of enrollment
? years
Age ?  years at time of consent ( years if required by local or state laws)
